4D Molecular Therapeutics (FDMT) Retained Earnings (2019 - 2025)
Historic Retained Earnings for 4D Molecular Therapeutics (FDMT) over the last 7 years, with Q3 2025 value amounting to -$735.7 million.
- 4D Molecular Therapeutics' Retained Earnings fell 3972.79% to -$735.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$735.7 million, marking a year-over-year decrease of 3972.79%. This contributed to the annual value of -$576.2 million for FY2024, which is 3873.29% down from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Retained Earnings is -$735.7 million, which was down 3972.79% from -$678.8 million recorded in Q2 2025.
- 4D Molecular Therapeutics' 5-year Retained Earnings high stood at -$152.1 million for Q1 2021, and its period low was -$735.7 million during Q3 2025.
- Moreover, its 5-year median value for Retained Earnings was -$372.8 million (2023), whereas its average is -$388.6 million.
- In the last 5 years, 4D Molecular Therapeutics' Retained Earnings plummeted by 6369.44% in 2022 and then tumbled by 2947.96% in 2024.
- 4D Molecular Therapeutics' Retained Earnings (Quarter) stood at -$207.0 million in 2021, then plummeted by 51.93% to -$314.5 million in 2022, then tumbled by 32.06% to -$415.3 million in 2023, then tumbled by 38.73% to -$576.2 million in 2024, then decreased by 27.68% to -$735.7 million in 2025.
- Its Retained Earnings was -$735.7 million in Q3 2025, compared to -$678.8 million in Q2 2025 and -$624.2 million in Q1 2025.